GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004603410 | Cervix | CC | ATP metabolic process | 90/2311 | 277/18723 | 7.90e-19 | 2.36e-15 | 90 |
GO:00229049 | Cervix | CC | respiratory electron transport chain | 42/2311 | 114/18723 | 1.67e-11 | 4.77e-09 | 42 |
GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:00091449 | Cervix | CC | purine nucleoside triphosphate metabolic process | 29/2311 | 88/18723 | 3.62e-07 | 1.45e-05 | 29 |
GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
GO:00092058 | Cervix | CC | purine ribonucleoside triphosphate metabolic process | 27/2311 | 82/18723 | 9.24e-07 | 3.25e-05 | 27 |
GO:00091458 | Cervix | CC | purine nucleoside triphosphate biosynthetic process | 24/2311 | 69/18723 | 1.21e-06 | 4.15e-05 | 24 |
GO:00091998 | Cervix | CC | ribonucleoside triphosphate metabolic process | 28/2311 | 89/18723 | 1.65e-06 | 5.44e-05 | 28 |
GO:00067548 | Cervix | CC | ATP biosynthetic process | 21/2311 | 57/18723 | 1.91e-06 | 5.97e-05 | 21 |
GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
GO:00092068 | Cervix | CC | purine ribonucleoside triphosphate biosynthetic process | 23/2311 | 68/18723 | 3.47e-06 | 9.26e-05 | 23 |
GO:00092018 | Cervix | CC | ribonucleoside triphosphate biosynthetic process | 24/2311 | 74/18723 | 4.95e-06 | 1.24e-04 | 24 |
GO:00091419 | Cervix | CC | nucleoside triphosphate metabolic process | 31/2311 | 112/18723 | 9.38e-06 | 2.11e-04 | 31 |
GO:00091428 | Cervix | CC | nucleoside triphosphate biosynthetic process | 25/2311 | 85/18723 | 2.17e-05 | 3.89e-04 | 25 |
GO:19905428 | Cervix | CC | mitochondrial transmembrane transport | 26/2311 | 102/18723 | 2.10e-04 | 2.39e-03 | 26 |
GO:00196939 | Cervix | CC | ribose phosphate metabolic process | 72/2311 | 396/18723 | 4.49e-04 | 4.48e-03 | 72 |
GO:00092599 | Cervix | CC | ribonucleotide metabolic process | 70/2311 | 385/18723 | 5.35e-04 | 5.18e-03 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A12 | SNV | Missense_Mutation | | c.1243N>A | p.Asp415Asn | p.D415N | O75746 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SLC25A12 | SNV | Missense_Mutation | novel | c.710N>T | p.Ser237Ile | p.S237I | O75746 | protein_coding | tolerated(0.38) | benign(0.028) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SLC25A12 | SNV | Missense_Mutation | novel | c.569G>T | p.Arg190Ile | p.R190I | O75746 | protein_coding | deleterious(0) | possibly_damaging(0.482) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SLC25A12 | SNV | Missense_Mutation | novel | c.1915N>C | p.Tyr639His | p.Y639H | O75746 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A12 | SNV | Missense_Mutation | novel | c.112N>A | p.Asp38Asn | p.D38N | O75746 | protein_coding | deleterious(0.04) | benign(0.162) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
SLC25A12 | SNV | Missense_Mutation | | c.29N>A | p.Arg10Gln | p.R10Q | O75746 | protein_coding | deleterious(0.01) | possibly_damaging(0.784) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
SLC25A12 | SNV | Missense_Mutation | novel | c.1831N>A | p.Gly611Ser | p.G611S | O75746 | protein_coding | tolerated(0.06) | probably_damaging(0.97) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A12 | SNV | Missense_Mutation | novel | c.266N>T | p.Ser89Phe | p.S89F | O75746 | protein_coding | deleterious(0) | possibly_damaging(0.498) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A12 | SNV | Missense_Mutation | | c.1358N>A | p.Arg453His | p.R453H | O75746 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-BG-A0M3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A12 | SNV | Missense_Mutation | rs369666236 | c.1843N>A | p.Ala615Thr | p.A615T | O75746 | protein_coding | tolerated(0.65) | benign(0) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |